Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation

Reddy, Heather L.; Dayan, Anthony D.; Cavagnaro, Joy A.; Gad, Shayne C.; Li, Junzhi; Goodrich, Raymond P.

doi:10.1016/j.tmrv.2007.12.003

Cited by 118 publications

(94 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18] These processes have been shown to prevent lymphocyte replication, and, as discussed below, there is strong evidence that they prevent TA-GVHD, thereby precluding the need to identify susceptible patients and eliminating the expense and difficulties associated with irradiation of blood components. At present, no commercially available technology has been developed for the pathogen reduction of all blood components.…”

Section: Pathogen Reductionmentioning

confidence: 99%

See 1 more Smart Citation

Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Mintz

Wehrli

2009

Bone Marrow Transplant

View full text Add to dashboard Cite

Section: Pathogen Reductionmentioning

confidence: 99%

“…35 This process has been shown to be highly effective at reducing the risk of transfusion-transmitted microbial infection. 18 Intriguingly, Mirasol treatment has also been shown to prevent alloimmunization by plt transfusion in rats. 36 The Mirasol System has been shown to functionally inactivate WBC in blood components.…”

Section: Mirasolmentioning

confidence: 99%

Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Mintz

Wehrli

2009

Bone Marrow Transplant

View full text Add to dashboard Cite

“…Consequently pathogen reduction using riboflavin and UV light, which is a method by which infectious pathogens, including plasmodium in blood for transfusion are inactivated by adding riboflavin and irradiating with UV light , is another effort in transfusion medicine to ensure blood safety. (Hardwick et al, 2004;Reddy et al, 2008;Sullivan et al, 2008). This lack of routine screening poses a particular risk to vulnerable blood recipients who include visitors to the region, little children who have not acquired partial immunity, pregnant women who are not on routine malaria prophylaxis, probably HIV/AIDS patients and other people with low immune status.…”

Section: Introductionmentioning

confidence: 99%

Malaria parasitaemia among blood donors in Ilorin, Nigeria

Olawumi¹,

Fadeyi²,

Babatunde³

et al. 2015

African Journal of Infectious Diseases

View full text Add to dashboard Cite

Background: The prevalence of malaria parasitaemia among blood donors in Ilorin has not been documented. In this study, we determined the prevalence of malaria parasitaemia among blood donors in Ilorin, as well as, the sociodemographic and other factors associated with it. Method: This was a hospital-based cross sectional study involving 308 consenting blood donors. The sociodemographic characteristics of participants as well as blood donation history were obtained using structured questionnaires specifically designed for this purpose. Giemsastained thick and thin blood films to identify malaria parasites were performed using standard method. ABO blood grouping and haemoglobin electrophoresis tests were also done using standard methods. Results: The prevalence of malaria parasitaemia among blood donors in Ilorin was 27.3%. The parasite species found were more of Plasmodium falciparum(85.7%) than Plasmodium malariae(14.3%) . There was no age or sex difference in malaria parasitaemia. (p-value of 0.8 and 0.32 respectively). A greater proportion of blood group O individuals had malaria parasitaemia than groups A and B but this difference was not significant (p-value = 0.13). There was also no significant difference among haemoglobin genotypes. Conclusion:The prevalence of malaria parasites among blood donors in Ilorin is considerably high and lack of routine screening of blood puts recipients at risk. We recommend that routine screening for malaria parasites be commenced in our blood banks. Treatment of donor blood with riboflavin and UV light to inactivate malaria parasites and other infectious pathogens before they are transfused to patients may also be considered in our blood banks.

show abstract

“…Using riboflavin as a photosensitizer, in combination with UV light, has been shown to reduce the infectivity of a broad range of pathogenic blood-borne contaminants, including bacteria 3,4,8,10,[19][20][21] .The use of riboflavin and UV light for pathogen reduction is non-toxic and non-mutagenic, and riboflavin and UV light-treated components have been shown to be safe for transfusion recipients as well as for those handling blood products 18 . Briefly, riboflavin molecules can associate with the nucleic acids (DNA and RNA) of bacteria, parasites, viruses and any nucleated cell (e.g.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Keil

Hovenga

Gilmour

et al. 2015

JoVE

View full text Add to dashboard Cite

Contamination of platelet units by bacteria has long been acknowledged as a significant transfusion risk due to their post-donation storage conditions. Products are routinely stored at 22 °C on an agitating shaker, a condition that can promote bacterial growth. Although the total number of bacteria believed to be introduced into a platelet product is extremely low, these bacteria can multiply to a very high titer prior to transfusion, potentially resulting in serious adverse events. The aim of this study was to evaluate a riboflavin based pathogen reduction process against a panel of bacteria that have been identified as common contaminants of platelet products. This panel included the following organisms: S. epidermidis, S. aureus, S. mitis, S. pyogenes, S. marcescens, Y. enterocolitica, B. neotomae, B. cereus, E. coli, P. aeruginosa and K. pneumoniae. Each platelet unit was inoculated with a high bacterial load and samples were removed both before and after treatment. A colony forming assay, using an end point dilution scheme, was used to determine the pre-treatment and post-treatment bacterial titers. Log reduction was calculated by subtracting the post-treatment titer from the pre-treatment titer. The following log reductions were observed: S. epidermidis 4.7 log (99.998%), S. aureus 4.8 log (99.998%), S. mitis 3.7 log (99.98%), S. pyogenes 2.6 log (99.7%), S. marcescens 4.0 log (99.99%), Y. enterocolitica 3.3 log (99.95%), B. neotomae 5.4 log (99.9996%), B. cereus 2.6 log (99.7%), E. coli ≥5.4 log (99.9996%), P. aeruginosa 4.7 log (99.998%) and K. pneumoniae 2.8 log (99.8%). The results from this study suggest the process could help to lower the risk of severe adverse transfusion events associated with bacterial contamination.

show abstract

Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation

Cited by 118 publications

References 74 publications

Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products

Malaria parasitaemia among blood donors in Ilorin, Nigeria

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

Contact Info

Product

Resources

About